Abstract
Background: Whole-slide imaging and algorithmic advances have moved computational pathology from research to routine consideration. Despite notable successes, real-world deployment remains limited by generalization, validation gaps, and human-factor risks, which can be amplified in resource-constrained settings. Content/Scope: This narrative review and implementation perspective summarizes clinically proximate AI capabilities in cancer pathology, including lesion detection, metastasis triage, mitosis counting, immunomarker quantification, and prediction of selected molecular alterations from routine histology. We also summarize recurring failure modes, dataset leakage, stain/batch/site shifts, misleading explanation overlays, calibration errors, and automation bias, and distinguish applications supported by external retrospective validation, prospective reader-assistance or real-world studies, and regulatory-cleared use. We translate these evidence patterns into a practical checklist covering dataset design, external and temporal validation, robustness testing, calibration and uncertainty handling, explainability sanity checks, and workflow-safety design. Equity Focus: We propose a stepwise adoption pathway for low- and middle-income countries: prioritize narrow, high-impact use cases; match compute and storage requirements to local infrastructure; standardize pre-analytics; pool validation cohorts; and embed quality management, privacy protections, and audit trails. Conclusions: AI can already serve as a reliable second reader for selected tasks, reducing variance and freeing expert time. Safe, equitable deployment requires disciplined validation, calibrated uncertainty, and guardrails against human-factor failure. With pragmatic scoping and shared infrastructure, pathology programs can realize benefits while preserving trust and accountability.